Association of glucagon-like peptide-1 receptor agonists with atrial fibrillation recurrence after catheter ablation: a systematic review and meta-analysis - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Link Between Glucagon-Like Peptide-1 Receptor Agonists and Atrial Fibrillation Recurrence Post-Catheter Ablation: A Systematic Review and Meta-Analysis

  • By

  • Dan He

  • Defu Lv

  • Jiaxin Tang

  • Xiaojuan Liao

  • Ping Mao

  • Zhu Tian

  • August 27, 2026

Share

  • 1

    A systematic review and meta-analysis assessed the relationship between GLP-1RA use and atrial fibrillation recurrence after catheter ablation.

  • 2

    Seven studies with 7,907 patients indicated that GLP-1RA use was associated with a lower risk of AF recurrence post-ablation (HR = 0.52, P < 0.001).

  • 3

    The protective association of GLP-1RAs against AF recurrence remained consistent across various subgroups, including sample size and study design.

  • 4

    For studies with ≤200 patients, the hazard ratio was 0.34, while for those with >200 patients, it was 0.70, indicating varying effects based on sample size.

  • 5

    Despite the findings, the protective effect of GLP-1RAs on AF recurrence remains inconclusive due to limitations and the need for further high-quality trials.

Original Source(s)

Association of glucagon-like peptide-1 receptor agonists with atrial fibrillation recurrence after catheter ablation: a systematic review and meta-analysis

  • by Dan He, Defu Lv, Jiaxin Tang, Xiaojuan Liao, Ping Mao, Zhu Tian

  • August 27, 2026

Related Content

Documented risk-based antithrombotic management and 30-day outcomes after endoscopic hemostasis for non-variceal upper gastrointestinal bleeding: a retrospective cohort study

Myocardial function recovery in peripartum cardiomyopathy: the role of global longitudinal strain and myocardial work

TOFA may drive weight loss without reducing food intake

The oral compound increased energy expenditure, reduced fat mass, and improved metabolic measures in male mouse models.